Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
TRS Stock Summary
Top 10 Correlated ETFs
TRS
In the News
Weakness in Specialty Products, High Costs Ail TriMas (TRS)
TriMas' (TRS) results will bear the brunt of the recent weakness in industrial cylinder demand, as well as high costs and labor shortages.
TriMas (TRS) Earnings Miss Estimates in Q4, Revenues Rise Y/Y
TriMas' (TRS) Q4 top line reflects organic growth in the aerospace and defense business.
TriMas Corporation (TRS) Q4 2023 Earnings Call Transcript
TriMas Corporation (TRS) Q4 2023 Earnings Call Transcript
Is TriMas (TRS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
TriMas Announces Fourth Quarter and Full Year 2023 Earnings Conference Call Date
BLOOMFIELD HILLS, Mich.--(BUSINESS WIRE)--TriMas (NASDAQ: TRS) announced today that it will host its fourth quarter and full year 2023 earnings conference call on Thursday, February 29, 2024. The conference call will begin at 10 a.m. Eastern Time and will follow the Company's release of fourth quarter and full year 2023 earnings results at 8 a.m. that day. To participate on the earnings conference call, please dial: (877) 407-0890 (U.S. and Canada) or +1 (201) 389-0918 (outside the U.S. and Can.
5 Metal Fabrication Stocks to Watch in a Challenging Industry
Low order levels cloud the near-term prospects of the Zacks Metal Products - Procurement and Fabrication industry. However, the likes of NHYDY, SKFRY, ESAB, CENX and TRS seem well-poised to tide over the hurdles.
TriMas (TRS) Expands Life Sciences' Cleanroom Capabilities
TriMas (TRS) expands the cleanroom capabilities of its Life Sciences division as part of its long-term strategic enhancement.
TriMas (TRS) Stock Down 7% in a Year: Will It Bounce Back in 2024?
TriMas' (TRS) results and price performance have been mirroring the persisting weakness in packaging demand, escalating raw material costs and supply-chain constraints.
TriMas Corporation (TRS) Q3 2023 Earnings Call Transcript
TriMas Corporation Q3 2023 Results Conference Call October 26, 2023 10:00 AM ET Company Participants Sherry Lauderback - Investor Relations and Communications Thomas Amato - President, CEO and Director Scott Mell - CFO & Principal Accounting Officer Conference Call Participants Hamed Khorsand - BWS Financial Katie Fleischer - KeyBanc Capital Markets Operator Greetings, and welcome to the TriMas Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
TriMas (TRS) Q3 Earnings Surpass Estimates
TriMas (TRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.40 per share a year ago.
TRS Financial details
TRS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 15.97 | 17.67 | 19.93 | 20.92 | 21.56 | |
Net income per share | 1.37 | -1.83 | 1.33 | 1.57 | 0.97 | |
Operating cash flow per share | 1.67 | 2.92 | 3.12 | 1.72 | 2.13 | |
Free cash flow per share | 1.01 | 1.99 | 2.07 | 0.63 | 0.82 | |
Cash per share | 3.81 | 1.7 | 3.27 | 2.65 | 0.84 | |
Book value per share | 15.4 | 13.41 | 14.67 | 15.43 | 16.48 | |
Tangible book value per share | 4.45 | 1.7 | 2.76 | 2.93 | 3.33 | |
Share holders equity per share | 15.4 | 13.41 | 14.67 | 15.43 | 16.48 | |
Interest debt per share | 7.44 | 9.16 | 10.7 | 10.84 | 10.12 | |
Market cap | 1.42B | 1.38B | 1.59B | 1.17B | 1.05B | |
Enterprise value | 1.57B | 1.69B | 1.9B | 1.5B | 1.46B | |
P/E ratio | 22.97 | -17.3 | 27.77 | 17.71 | 26.01 | |
Price to sales ratio | 1.97 | 1.79 | 1.86 | 1.33 | 1.17 | |
POCF ratio | 18.82 | 10.83 | 11.86 | 16.15 | 11.91 | |
PFCF ratio | 30.98 | 15.88 | 17.85 | 44.04 | 30.9 | |
P/B Ratio | 2.04 | 2.36 | 2.52 | 1.8 | 1.54 | |
PTB ratio | 2.04 | 2.36 | 2.52 | 1.8 | 1.54 | |
EV to sales | 2.17 | 2.2 | 2.21 | 1.7 | 1.63 | |
Enterprise value over EBITDA | 11.58 | 17.32 | 13.82 | 11.3 | 10.83 | |
EV to operating cash flow | 20.81 | 13.27 | 14.13 | 20.72 | 16.54 | |
EV to free cash flow | 34.26 | 19.45 | 21.27 | 56.52 | 42.92 | |
Earnings yield | 0.04 | -0.06 | 0.04 | 0.06 | 0.04 | |
Free cash flow yield | 0.03 | 0.06 | 0.06 | 0.02 | 0.03 | |
Debt to equity | 0.46 | 0.66 | 0.71 | 0.68 | 0.59 | |
Debt to assets | 0.27 | 0.32 | 0.34 | 0.34 | 0.3 | |
Net debt to EBITDA | 1.11 | 3.18 | 2.22 | 2.49 | 3.03 | |
Current ratio | 3.62 | 2.56 | 2.79 | 3.02 | 2.49 | |
Interest coverage | 6.54 | 3.26 | 6.55 | 7.02 | 4.84 | |
Income quality | 0.77 | -1.6 | 2.34 | 1.1 | 2.18 | |
Dividend Yield | 0 | 0 | 0 | 0.01 | 0.01 | |
Payout ratio | 0 | 0 | 0.03 | 0.1 | 0.17 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.42 | 0.43 | 0.39 | 0.4 | 0.41 | |
Capex to operating cash flow | -0.39 | -0.32 | -0.34 | -0.63 | -0.61 | |
Capex to revenue | -0.04 | -0.05 | -0.05 | -0.05 | -0.06 | |
Capex to depreciation | -0.68 | -0.81 | -0.84 | -0.86 | -0.94 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Graham number | 21.76 | 23.5 | 20.97 | 23.32 | 19 | |
ROIC | 0.07 | 0.04 | 0.07 | 0.07 | 0.05 | |
Return on tangible assets | 0.09 | -0.12 | 0.07 | 0.09 | 0.05 | |
Graham Net | -3.86 | -8.63 | -8.41 | -8.52 | -10.05 | |
Working capital | 314.25M | 214.64M | 276.87M | 282.51M | 237.93M | |
Tangible asset value | 201.45M | 74.08M | 118.63M | 123.91M | 138.16M | |
Net current asset value | -61.18M | -257.8M | -241.02M | -230.51M | -261.33M | |
Invested capital | 0.46 | 0.66 | 0.71 | 0.68 | 0.59 | |
Average receivables | 115.99M | 111.14M | 119.52M | 129M | 140.2M | |
Average payables | 83.05M | 71.29M | 78.86M | 86.51M | 88.56M | |
Average inventory | 152.89M | 141.02M | 150.92M | 157.91M | 177.91M | |
Days sales outstanding | 54.92 | 53.76 | 53.5 | 54.67 | 60.47 | |
Days payables outstanding | 50.08 | 43.4 | 50.08 | 46.04 | 48.01 | |
Days of inventory on hand | 91.42 | 92.74 | 86.96 | 88.27 | 100.54 | |
Receivables turnover | 6.65 | 6.79 | 6.82 | 6.68 | 6.04 | |
Payables turnover | 7.29 | 8.41 | 7.29 | 7.93 | 7.6 | |
Inventory turnover | 3.99 | 3.94 | 4.2 | 4.14 | 3.63 | |
ROE | 0.09 | -0.14 | 0.09 | 0.1 | 0.06 | |
Capex per share | -0.65 | -0.93 | -1.05 | -1.09 | -1.31 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 4.85 | 5.19 | 5.62 | 5.68 | 5.07 | |
Net income per share | 0.45 | 0.12 | 0.27 | 0.4 | 0.19 | |
Operating cash flow per share | 0.62 | 0.23 | 0.4 | 0.76 | 0.74 | |
Free cash flow per share | 0.28 | -0.12 | 0.15 | 0.52 | 0.27 | |
Cash per share | 2.67 | 1.25 | 1.01 | 0.84 | 0.84 | |
Book value per share | 15.55 | 15.62 | 15.97 | 16.29 | 16.53 | |
Tangible book value per share | 2.96 | 2.22 | 2.63 | 3.18 | 3.34 | |
Share holders equity per share | 15.55 | 15.62 | 15.97 | 16.29 | 16.53 | |
Interest debt per share | 10.68 | 10.83 | 11.33 | 10.85 | 9.87 | |
Market cap | 1.16B | 1.16B | 1.14B | 1.03B | 1.05B | |
Enterprise value | 1.49B | 1.55B | 1.56B | 1.44B | 1.46B | |
P/E ratio | 15.43 | 58.93 | 25.86 | 15.55 | 32.96 | |
Price to sales ratio | 5.72 | 5.37 | 4.89 | 4.36 | 5 | |
POCF ratio | 44.83 | 119.44 | 69.08 | 32.69 | 34.22 | |
PFCF ratio | 98.43 | -226.94 | 179.21 | 48 | 92.31 | |
P/B Ratio | 1.78 | 1.78 | 1.72 | 1.52 | 1.53 | |
PTB ratio | 1.78 | 1.78 | 1.72 | 1.52 | 1.53 | |
EV to sales | 7.35 | 7.2 | 6.71 | 6.1 | 6.94 | |
Enterprise value over EBITDA | 139.14 | 66.68 | 42.71 | 38.39 | 47.17 | |
EV to operating cash flow | 57.63 | 160.13 | 94.77 | 45.77 | 47.57 | |
EV to free cash flow | 126.54 | -304.26 | 245.86 | 67.21 | 128.32 | |
Earnings yield | 0.02 | 0 | 0.01 | 0.02 | 0.01 | |
Free cash flow yield | 0.01 | 0 | 0.01 | 0.02 | 0.01 | |
Debt to equity | 0.68 | 0.69 | 0.7 | 0.66 | 0.59 | |
Debt to assets | 0.34 | 0.34 | 0.34 | 0.33 | 0.3 | |
Net debt to EBITDA | 30.91 | 16.94 | 11.58 | 10.98 | 13.24 | |
Current ratio | 3.02 | 2.63 | 2.7 | 2.59 | 2.49 | |
Interest coverage | -0.71 | 2.7 | 5.05 | 6.02 | 3.93 | |
Income quality | 1.38 | 1.97 | 1.5 | 1.9 | 3.85 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0.09 | 0.34 | 0.15 | 0.1 | 0.21 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0.4 | 0.42 | 0.41 | 0.4 | 0.41 | |
Capex to operating cash flow | -0.54 | -1.53 | -0.61 | -0.32 | -0.63 | |
Capex to revenue | -0.07 | -0.07 | -0.04 | -0.04 | -0.09 | |
Capex to depreciation | -1.06 | -1.11 | -0.62 | -0.72 | -1.38 | |
Stock based compensation to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0 | |
Graham number | 12.54 | 6.44 | 9.77 | 12.08 | 8.45 | |
ROIC | 0 | 0.01 | 0.01 | 0.02 | 0.01 | |
Return on tangible assets | 0.02 | 0.01 | 0.01 | 0.02 | 0.01 | |
Graham Net | -8.59 | -10.13 | -10.55 | -10.06 | -10.08 | |
Working capital | 282.51M | 242.5M | 258.32M | 249.87M | 237.93M | |
Tangible asset value | 123.91M | 92.33M | 108.88M | 131.7M | 138.16M | |
Net current asset value | -230.51M | -279.37M | -284.06M | -259.55M | -261.33M | |
Invested capital | 0.68 | 0.69 | 0.7 | 0.66 | 0.59 | |
Average receivables | 137.49M | 140.98M | 157.19M | 165.31M | 156.93M | |
Average payables | 89.29M | 85.49M | 84.78M | 82.66M | 86.72M | |
Average inventory | 168.55M | 167.56M | 177.14M | 182.43M | 187.39M | |
Days sales outstanding | 58.6 | 62.48 | 63.6 | 63.41 | 63.57 | |
Days payables outstanding | 48.62 | 46.01 | 42.2 | 40.9 | 49.69 | |
Days of inventory on hand | 93.21 | 92.14 | 91.94 | 91.46 | 104.05 | |
Receivables turnover | 1.54 | 1.44 | 1.41 | 1.42 | 1.42 | |
Payables turnover | 1.85 | 1.96 | 2.13 | 2.2 | 1.81 | |
Inventory turnover | 0.97 | 0.98 | 0.98 | 0.98 | 0.87 | |
ROE | 0.03 | 0.01 | 0.02 | 0.02 | 0.01 | |
Capex per share | -0.34 | -0.36 | -0.24 | -0.24 | -0.47 |
TRS Frequently Asked Questions
What is TriMas Corporation stock symbol ?
TriMas Corporation is a US stock , located in Bloomfield hills of Mi and trading under the symbol TRS
What is TriMas Corporation stock quote today ?
TriMas Corporation stock price is $26.67 today.
Is TriMas Corporation stock public?
Yes, TriMas Corporation is a publicly traded company.